Startups
Ovid Therapeutics
New York, New York, United States
New York biotechnology company developing small molecule medicines for epilepsies and other brain disorders associated with neuronal hyperexcitability. Co-founded in April 2014 by neuroscientist Matthew During and physician Jeremy Levin, it listed on Nasdaq in 2017 under OVID. Its current pipeline includes OV329, a next-generation GABA-aminotransferase inhibitor, in Phase 2 studies, and OV4071, an oral KCC2 activator, in Phase 1, as reported in August 2026. Meg Alexander became CEO in January 2026, with Levin continuing as executive chairman. Ovid holds equity investments in Graviton Bioscience and Gensaic and received equity in a Perceptive-backed soticlestat company in exchange for rights. Its partnered OV888/GV101 program was paused in late 2024. No company AI discovery platform has been verified.
Founded 2014
Team
 Anna GrekaBoard Member |
 Barbara DuncanBoard Member |
 Bart FriedmanLead Independent Director |
 Charles CarterChief Financial Officer |
 Eliseo SalinasSenior R&D Advisor |
 Imad NajmScientific and Clinical Advisory Board Member |
 Issam AwadScientific and Clinical Advisory Board Member |
 Jacqueline FrenchScientific and Clinical Advisory Board Member |
 Jamie MaguireScientific and Clinical Advisory Board Member |
 Jeffrey NoebelsScientific and Clinical Advisory Board Member |
Jeffrey RonaAdvisor |
 Jeremy LevinCo-Founder & Executive Chairman |
 Julia TsaiSenior Vice President of Clinical Development |
 Kevin FitzgeraldBoard Member |
 Kevin NorrettChief Business Officer |
Matthew DuringCo-Founder (historical) |
 Meg AlexanderPresident & Chief Executive Officer · Board Member |
 Petra KaufmannChief Medical Officer |
 Raman SankarScientific and Clinical Advisory Board Member |
 Robert LangerChairman, Scientific and Clinical Advisory Board |
 Stelios PapadopoulosBoard Member |
 Victoria FortChief Strategy Officer |
 Zhong ZhongChief Scientific Officer |
